Characteristics of Real-World Patients with High-Risk BRAF^V600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

Pietro Quaglino1 Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy

Paolo A Ascierto2 Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy

Francesca Consoli3 Department of Oncology, ASST Spedali Civili, Brescia, Italy

Paola Queirolo4 Oncology Division, Policlinico San Martino IRCCS, Genova, Italy, and Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy

Francesco Spagnolo5 Skin Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy

Maria Francesca Morelli6 Department of Oncology and Dermatological Oncology, Istituto Dermopatico dell’Immacola, Rome, Italy

Rossana Berardi7 Università Politecnica delle Marche – Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy

Vanna Chiarion-Sileni8 Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy

Marco Tucci9 Medical Oncology Unit, Department of Interdisciplinary Medicine, University of Bari ‘Aldo Moro’, Bari, Italy

Teresa Troiani10 Faculty of Medicine, Second University of Naples, Naples, Italy

Barbara Melotti11 Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

Ernesto Rossi12 Medical Oncology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy

Mario Mandala13 Division of Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy, and University of Perugia, Perugia, Italy

Gaetana Rinaldi14 UOC Oncologia Medica Aoup Paolo Giaccone, Palermo, Italy

Ilaria Gioia Marcon15 Novartis Farma S.p.A, Milan, Italy

Matteo Pizzuti15 Novartis Farma S.p.A, Milan, Italy

Michele Del Vecchio16 Unit of Melanoma Medical Oncology, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyCorrespondence[email protected]

show all

Characteristics of Real-World Patients with High-Risk BRAF^V600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Characteristics of Real-World Patients with High-Risk BRAF^V600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program